{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intermittent+dosing+of+AZD5363",
    "query": {
      "intervention": "Intermittent dosing of AZD5363"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T16:06:11.384Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01692262",
      "title": "Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castrate-Resistant Prostate Cancer (mCRPC),",
        "Efficacy,",
        "Safety and Tolerability,",
        "Pharmacokinetics,",
        "Pharmacodynamics,",
        "Tumour Response."
      ],
      "interventions": [
        {
          "name": "Intermittent dosing of AZD5363",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 59,
      "start_date": "2012-11",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-19",
      "last_synced_at": "2026-09-29T16:06:11.384Z",
      "location_count": 5,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01692262"
    },
    {
      "nct_id": "NCT02208375",
      "title": "mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BRCA1 Mutation Carrier",
        "BRCA2 Mutation Carrier",
        "Endometrial Adenocarcinoma",
        "Estrogen Receptor Negative",
        "HER2/Neu Negative",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Progesterone Receptor Negative",
        "Recurrent Breast Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Uterine Corpus Carcinoma",
        "Stage III Uterine Corpus Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Uterine Corpus Cancer AJCC v7",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vistusertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 159,
      "start_date": "2014-11-11",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-09-29T16:06:11.384Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02208375"
    },
    {
      "nct_id": "NCT01226316",
      "title": "Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Malignancy",
        "Safety and Tolerability",
        "Pharmacokinetics",
        "Pharmacodynamics",
        "Tumour Response",
        "Advanced or Metastatic Breast Cancer",
        "Ovarian Cancer",
        "Cervical Cancer",
        "Endometrial Cancer",
        "PIK3CA",
        "AKT1",
        "PTEN",
        "ER Positive",
        "HER2 Positive"
      ],
      "interventions": [
        {
          "name": "AZD5363",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 285,
      "start_date": "2010-12-01",
      "completion_date": "2024-12-03",
      "has_results": false,
      "last_update_posted_date": "2025-06-29",
      "last_synced_at": "2026-09-29T16:06:11.384Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Stanford, California • West Hollywood, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01226316"
    },
    {
      "nct_id": "NCT03997123",
      "title": "Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple Negative Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 923,
      "start_date": "2019-06-25",
      "completion_date": "2026-03-16",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-09-29T16:06:11.384Z",
      "location_count": 22,
      "location_summary": "Whittier, California • Fort Myers, Florida • Miami, Florida + 18 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03997123"
    }
  ]
}